EPO granted Patent EP3884049A1 to uniQure IP B.V. covering liver-specific viral promoters and methods of using the same in gene therapy. The patent application (filed under IPC classifications C12N 15/11, C07K 14/755, C12N 15/79) names eight inventors including Lubelski, du Plessis, Liu, ter Brake, and others. The designation covers all standard EPO member states including AT, BE, CH, DE, ES, FR, GB, IT, NL, and others.\n\nThis patent grant affects companies developing AAV-based or other viral vector gene therapies targeting liver tissue. Freedom-to-operate analyses should incorporate this IP position. No immediate compliance actions are required, but companies in the gene therapy space should review their pipeline technologies against this newly granted patent claims to assess potential licensing needs or design-around strategies.